OAC
BDTX icon

OMERS Administration Corp’s Black Diamond Therapeutics BDTX Stock Holding History

OMERS Administration Corp’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-62,800
Closed -$134K – 937
2026
Q1 		$134K Sell
62,800
-76,100
-55% -$181K ﹤0.01% 976
2025
Q4 		$338K Buy
138,900
+127,900
+1,163% +$453K ﹤0.01% 783
2025
Q3 		$41.7K Buy
+11,000
New +$32.2K ﹤0.01% 1102
2024
Q2 		– Sell
-21,200
Closed -$107K – 1055
2024
Q1 		$107K Buy
+21,200
New +$85.5K ﹤0.01% 320

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

OMERS Administration Corp's BDTX Position: Q2 2026 in Review

OMERS Administration Corp sold out of Black Diamond Therapeutics (BDTX) in Q2 2026, closing a stake of 62,800 shares — an estimated $134K sold.

OMERS Administration Corp first reported a position in BDTX in Q1 2024 and held it in 4 quarters. The position peaked at $338K in Q4 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • OMERS Administration Corp reported no remaining Black Diamond Therapeutics position as of Q2 2026 after selling out during the quarter.
  • OMERS Administration Corp sold 62,800 Black Diamond Therapeutics shares in Q2 2026, an estimated $134K.
  • OMERS Administration Corp first reported a position in Black Diamond Therapeutics in Q1 2024 and held it in 4 quarters.
  • OMERS Administration Corp's Black Diamond Therapeutics position peaked at $338K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on OMERS Administration Corp's 13F filing for Q2 2026, filed 13 Aug 2026.